Phase III Clinical Readiness
Accelerating the next generation of molecular precision.
Synthesizing advanced diagnostics with targeted therapies to address unmet clinical needs in oncology and neuro-immunology through evidence-led investigation.
01. Treatments
RNA-Targeted Modalities
Stable molecular frameworks that modulate protein expression with surgical precision at the cellular level.
02. Diagnostics
Multi-omic Screening
Predictive algorithms and deep sequencing identify disease biomarkers long before clinical manifestation.
03. Therapies
Adaptive Immunotherapy
Re-engineering patient immune responses through proprietary T-cell modification protocols and clinical validation.
Clinical Investigations
Rigorous testing phases currently in collaboration with university research hospitals.
ST-402 // NEUROLOGY
Amyloid Plaque Reduction Study
StatusRecruiting
PhasePhase III
ST-109 // ONCOLOGY
Solid Tumor Microenvironment Modulation
StatusIn Progress
PhasePhase IIa
ST-771 // RARE DISEASE
Enzyme Replacement Delivery Optimization
StatusData Analysis
PhasePhase I
Institutional Partners & Scientific Affiliations
Stanford MedicineMayo ClinicOxford UniversityBroad InstituteUCSF Research